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ABSTRACT
Here, we propose a framework for the design of
synthetic protein networks from modular protein–
protein or protein–peptide interactions and provide
a starter toolkit of protein building blocks. Our proof
of concept experiments outline a general work flow
for part–based protein systems engineering. We
streamlined the iterative BioBrick cloning protocol
and assembled 25 synthetic multidomain proteins
each from seven standardized DNA fragments.
A systematic screen revealed two main factors
controlling protein expression in Escherichia coli:
obstruction of translation initiation by mRNA
secondary structure or toxicity of individual
domains. Eventually, 13 proteins were purified for
further characterization. Starting from well-
established biotechnological tools, two general–
purpose interaction input and two readout devices
were built and characterized in vitro. Constitutive
interaction input was achieved with a pair of
synthetic leucine zippers. The second interaction
was drug-controlled utilizing the rapamycin-
induced binding of FRB(T2098L) to FKBP12. The
interaction kinetics of both devices were analyzed
by surface plasmon resonance. Readout was based
on Fo ¨rster resonance energy transfer between
fluorescent proteins and was quantified for various
combinations of input and output devices. Our
results demonstrate the feasibility of parts-based
protein synthetic biology. Additionally, we identify
future challenges and limitations of modular
design along with approaches to address them.
INTRODUCTION
Cells rely on networks of interacting proteins for the
fast integration and processing of information.
Complementary changes in gene regulation require the
time- and energy-consuming steps of transcription and
translation. By comparison, protein regulatory networks
are often already in place and merely need to be modiﬁed
or re-arranged (1). Protein signaling is thus faster and,
thanks to an amazing repertoire of protein functionalities,
also much more versatile. Several recent studies have
begun to re-route and manipulate the dynamics of
natural protein networks (2–4). Nevertheless, major
concepts of synthetic biology have been primarily tested
on the level of gene (5) or RNA regulatory systems (6).
The engineering of systems from ‘standard biological
parts’ (7–9) is one of these prevailing visions of synthetic
biology. Parts are considered to be the smallest unit
of engineering, typically encoded by a single DNA
sequence and re-used for diﬀerent aims in diﬀerent
contexts. Examples from the world of gene regulation
include ribosomal binding sites (RBS), promoter regions,
and genes for transcription factors or reporters. Standards
are proposed that facilitate the physical exchange and
assembly of such building blocks (10) and foster their
reﬁnement based on shared experiences (9). Parts are
then combined into ‘devices’. Devices encapsulate a
certain function with deﬁned input and output. Basic
examples could be a genetic toggle switch (11) or the
AND gate within a RNA sensor (12). The notion of
devices helps to abstract away from the underlying
complexity and creates a higher level, functional rather
than physical, unit of engineering. Deﬁnitions of parts
and functional interfaces between devices can ultimately
converge into full-ﬂedged engineering frameworks. Such
frameworks of functional composition outline standard
boundaries between diﬀerent categories of devices and
set rules for their physical connection. Currently,
frameworks have been proposed for the composition of
transcription-based networks (7,13) as well as for the
engineering of RNA regulatory systems (6).
We have recently outlined the contours of an
engineering framework for protein synthetic biology (4).
We propose to utilize the natural modularity of many
proteins (14) and aim for the construction of synthetic
protein circuits from protein interaction devices. In fact,
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long been proven not only as a very eﬀective way to
interfere with cellular signaling (15), but have also been
employed for metabolic engineering (16) or therapeutic
targeting (17). Moreover, biochemists are routinely
trimming or disassembling natural proteins into their
globular domains or using fusions with various tags and
reporters for detection, puriﬁcation or life imaging. The
question is now whether we can bundle this know-how
into a synthetic biology framework of parts and devices
and whether we will thus indeed be able to tame the
intricate complexity of proteins and their networks.
Some of the key requirements will be: (i) catalogs of
reliable protein building blocks (parts); (ii) eﬃcient
DNA exchange formats and assembly methods for the
composition of multi-domain constructs; (iii) streamlined
protocols for protein production and characterization;
(iv) well-characterized interaction input devices to trigger
and control synthetic systems; (v) well-characterized
interaction readout devices to follow their dynamics.
Moreover, a rational design approach can build on the
in vitro characterization of proteins and quantify their
interactions in absolute biophysical measures.
Our proof of concept study elaborates on all ﬁve issues.
We examine the feasibility of a prototypical work ﬂow,
beginning with the assembly of synthetic protein
constructs from standard DNA parts, followed by
expression and puriﬁcation of proteins for biophysical
characterization. We provide a starter toolkit for the
design of protein interaction devices. We apply a
streamlined BioBrick (18,19) assembly protocol to the
construction of 25 synthetic two-domain fusion proteins
from a set of 12 diﬀerent globular domains as well as
linker and puriﬁcation tags. We evaluate the expression
of these proteins in Escherichia coli and obtain soluble,
puriﬁed samples for about half of them. The binding
kinetics of two diﬀerent interaction input devices is
characterized by surface plasmon resonance (SPR) and
we test the readout of interactions based on Fo ¨ rster
resonance energy transfer (FRET). Domain swap
experiments reveal factors limiting protein expression
and shed light on the modularity and composability of
simple input/output combinations.
All parts and constructs described in this article have
been submitted to the Registry of Standard Biological
Parts. Detailed protocols are maintained online on
the OpenWetware community collaboration portal
(http://www.openwetware.org). We aim to develop this
small initial library of building blocks into a larger
community-driven parts distribution for protein synthetic
biology.
MATERIALS AND METHODS
Basic BioBrick protein parts
DNA coding for individual (basic) BioBrick-formatted
protein parts was synthesized by GeneArt (Regensburg,
Germany) and sequence-optimized for expression in
E. coli. Parts were formatted as speciﬁed in BioBrick
Foundation Request for Comments (BBF RFC) 25 (20).
This standard proposal extends the classic BioBrick
format [BBF RFC 10 (18)] by two restriction sites for
in-frame protein fusions. Every part was thus preceded
by the extended RFC 25 BioBrick preﬁx GAATTCGCG
GCCGCTTCTAGATGGCCGGC (with restriction sites
EcoRI, NotI, XbaI, NgoMIV) and followed by the
extended BioBrick suﬃx ACCGGTTAATACTAGTAG
CGGCCGCTGCAG (with restriction sites AgeI, SpeI,
NotI, PstI). Codon optimization by GeneArt also
removed any of these restriction sites from the part
sequence itself. Every part is therefore compatible to
standard BioBrick assembly according to BBF RFC 10
as well as to protein fusion BioBrick assembly according
to BBF RFC 25. DNA constructs were delivered in
GeneArt vector backbone pMA (Registry part number
K157000).
Modiﬁcation of BioBrick construction vectors
Construction vectors pSB1AC3, pSB1AK3 and pSB1AT3
were obtained from the Registry of Standard Biological
Parts. The vector backbone without ccdB (part P1010)
insert was linearized by PCR introducing the RFC 25
extensions including NgoMIV and AgeI restriction sites.
The P1010 insert was ampliﬁed by PCR introducing 15-bp
overlap with the modiﬁed ends of the vector backbone.
The two overlapping PCR products were recombined
using the In-Fusion kit (Clonetech). Three NgoMIV
restriction sites within the Tc resistance cassette of
pSB1AT3 were subsequently deleted using the
QuickChange mutagenesis kit (Qiagen).
Streamlined BioBrick assembly
More detailed versions of these protocols are given at
http://openwetware.org/wiki/Prbbbb:vector_pcr (vector
backbone), http://openwetware.org/wiki/Prbbbb:fusion_
assembly_v1 (assembly) and http://openwetware.org/
wiki/PrbbBB:colony_pcr_v1 (colony screening).
A stock of 5  concentrated restriction mix A was
prepared containing 1U/ml EcoRI, 1U/ml AgeI, 5 
NEBuﬀer 1. Restriction mix B, 5  concentrated,
contained 1.6U/mlP s t I ,1 . 7U / mlN g o M I V ,5   NEBuﬀer 4,
5  BSA. A stock of 2  concentrated ligation mix
contained 40000U/ml T4 DNA ligase in 2  T4 buﬀer.
All plasmid DNA was normalized to a standard
concentration of 50ng/ml in water. Eight microliters of
part A plasmid DNA was digested for 2h with 2ml
restriction mix A (without further dilution). Eight
microliters of part B plasmid DNA was digested for 2h
with 2ml restriction mix B. Both restrictions were heat-
inactivated for 20min at 80 C. A stock of target vector
backbone C was prepared by PCR from vectors
pSB1AC3F, pSB1AK3F or pSB1AT3F using Phusion
polymerase (Finnzymes) with primers BBa_J18910
and BBa_J18911, treated with DpnI, desalted,
dephosphorylated with Antarctic phospatase, diluted to
a standard concentration of 25ng/ml and digested with
restriction mix C containing EcoRI and PstI, followed
by heat-inactivation. Four microliters of digest reaction
A, 4ml digest reaction B and 2ml digest reaction C
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for 1h at 16 C, heat-inactivated and 2ml were used for
transformation into 12ml Top10 chemically competent
cells (Invitrogen) according to the manufacturer’s
instruction. All restriction and ligation enzymes were
purchased from New England Biolabs (NEB).
Restrictions, ligations and transformation reactions were
laid out on 96-well PCR plates as described in Figure 1
and incubated on Thermocycler heat blocks. Clones were
selected by growth on agar plates containing either
chloramphenicol, kanamycin, or tetracycline (depending
on the target backbone).
Colony PCRs were performed on 96-well PCR plates
using AmpliTaq DNA Polymerase (Roche) and standard
sequencing primers BBa_G00100, and BBa_G00101 with
30 cycles at 64 C annealing temperatures. PCR products
were analyzed on agarose gels or on a Bioanalyzer
(Agilent). For each transformation, four clones were
screened and two positive clones were grown over night
in square-bottom 96-deep-well plates using volumes of
1.5–1.8ml 2xTY medium supplemented with appropriate
antibiotic, sealed with gas-transmissible adhesive tape and
incubated on a thermomixer (Eppendorf) at 37 C with
rigorous shaking. Aliquots of cells were mixed with
glycerol (20% ﬁnal concentration) and stored at  80 C
in 96-well plates. Remaining cells were harvested by
centrifugation at optical densities (OD) around 1.5 and
DNA isolated with a 96-well plate-based DNA miniprep
kit (Millipore) and eluted with water (MilliQ). DNA
concentrations were determined on a Nanodrop
spectrophotometer (ThermoScientiﬁc) or on a plate
reader (Tecan) using deﬁned volumes in 384 square-well
plates (UV-star, Greiner). DNA was diluted to 50ng/mli n
water and stored in 96-well plates at  20 C. Cell, DNA
samples and sequencing results were tracked together with
other part-related information in a custom-made
database-backed web server, BrickIt, which we have
made freely available under the GPL open source license
for customization and local deployment (http://brickit
.sf.net).
Figure 1. A streamlined BioBrick assembly protocol. The pairwise ligation of standardized parts was optimized for parallel processing on 96-well
plates and thermocycler heat blocks. Plasmids with BioBrick-formatted parts are double-digested with restriction mix A or B, triple-ligated into a
new vector backbone and transformed into competent cells. Transformants are screened by colony PCR and inoculated into deep-well plates for
robotic or manual DNA miniprep. Plasmid DNA is diluted to a standard concentration and stored for further assembly rounds.
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A detailed version of the expression protocol is hosted at
http://openwetware.org/wiki/Prbbbb:small_scale_expressi
on_v1. Plasmids with the expression constructs were
transformed into E. coli BL21(DE3) (Invitrogen) and
spread on LB agar plates supplemented with 1%
glucose, 100mg/ml Ampicilin as well as a second antibiotic
depending on the vector backbone (Kanamycin or
Chloramphenicol). Agar plates were incubated for
12–14h at 37 C. Two colonies each were picked into
1ml LB medium containing the same antibiotics and 1%
glucose and were incubated overnight shaking at 37 Ci na
96-deep-well (square wells) plate with gas-transmissible
sealing. Cell stocks were prepared with a ﬁnal
concentration of 10% glycerol and stored at  80 C.
Qualitative expression screen. A total of 2.5ml 2xTY
medium (with 1% glucose and both antibiotics) were
inoculated with 25ml from the same overnight culture
and incubated shaking until an OD of  0.4–0.8. Protein
expression was induced by adding IPTG to a ﬁnal
concentration of 0.5mM. Samples were immediately
split and two 1ml aliquots of each were incubated on
two diﬀerent 96-deep-well plates for expression at 37 C
and 20 C, respectively. Plates were sealed (gas-
transmissible) and incubated on a thermomixer
(Eppendorf) at 850r.p.m. The 37 C cultures were
harvested after 2.5h by centrifugation for 10min at
4000r.p.m. at 4 C and pellets were subsequently frozen
at  80 C. Cultures (20 C) were incubated over night
and equally harvested and frozen. Cells were lysed by
resuspension in 300ml BugBuster buﬀer (Novagen),
supplemented with 1 Tablet Complete mini protease
inhibitor (Roche) per 10ml lysis buﬀer. The lysis mix
was incubated for 20min shaking at room temperature.
Cell debris was removed by 5min centrifugation at 1500g
at 4 C. The supernatant was transferred from the 96-well
plate into 1.5ml Eppendorf tubes and subjected to 40min
centrifugation at 20000g and 4 C in order to split the
soluble from the insoluble fraction. Ten microliters of
the soluble fraction was denatured in sample buﬀer,
separated by SDS–PAGE under reducing conditions and
analyzed by western blotting with mouse monoclonal anti-
polyHistidine antibody (Sigma) detected with peroxidase-
conjugated sheep anti-mouse secondary antibody
(Jackson ImmunoResearch, Baltimore, MD, USA) using
Western Lighting ECL reagants (PerkinElmer). The
insoluble fraction was redissolved in 50ml5   SDS–
PAGE sample buﬀer, denatured and 5ml were analyzed
by SDS–PAGE and western blotting.
Quantitative puriﬁcation screen. For each protein
construct, we selected the clone with the highest soluble
expression for a 4-ml scale puriﬁcation screen. Starting
cultures were inoculated overnight as before, 4ml
production cultures (2xTY, 1% glucose, two antibiotics)
were inoculated 1:100 and incubated in 24-deep-well plates
at 37 C. Most clones were inoculated on two diﬀerent
plates for expression at 37 C (all clones) and at 20 C
(all but those with no expression at 20 C during the
qualitative screen). Cultures were grown to OD of
0.4–0.8, switched to expression temperature, induced
with IPTG at 0.5mM and incubated shaking at
850r.p.m. for 3h (37 C) or 18h (20 C). The ﬁnal OD
was measured, cells were harvested, frozen and lysed as
described above (using 600ml BugBuster buﬀer per
sample) and split into soluble fraction and insoluble
pellet. Pellets were re-dissolved in 500ml solubilization
buﬀer (50mM HEPES, 0.5M NaCl, 5mM DTT, 1%
Triton-X, 20mM imidazole, 8M urea, pH 7.4). Soluble
and insoluble fractions were then subjected to Ni
2+-
aﬃnity puriﬁcation on HisMultiTrapHP 96-well plates
(GE Healthcare) according to the manufacturer’s
instructions and eluted with elution buﬀer (20mM
sodium phosphate, 500mM NaCl, 500mM imidazole,
pH 7.4). Eluates were probed by western blotting as
before. Wash and eluate fractions were then analyzed on
a 2100 BioAnalyzer capillary electrophoresis device
(Agilent) using the Protein 80 kit according to the
manufacturer’s instructions. Protein concentrations were
quantiﬁed by automatic integration of elution proﬁles
with the BioAnalyzer software. Two clones each of 10
potentially toxic protein constructs (plus 2 controls)
were subjected to another expression/puriﬁcation screen
after transformation into BL21(DE3)pLysE (Invitrogen)
and growth in LB (rather than 2xTY) at 20 C.
RBS eﬃciency calculation. Each construct’s leading
200bp (80bp before and 117bp after the start codon)
were submitted to the RBS calculator web server at
http://voigtlab.ucsf.edu/software/. Each protein yield was
normalized by the sample’s ﬁnal OD600 and mapped
against the RBS score.
Large-scale protein puriﬁcation
Each construct’s best-performing clone was re-streaked
from the cell stock onto LB plates supplemented
with 1% glucose, ampicilin and kanamycin or
chloramphenicol. Ten milliliters 2xTY (+1% glucose
and the two appropriate antibiotics) were inoculated
from a single fresh colony and incubated shaking over
night at 37 C. Cells were pelleted by centrifugation,
resuspended in 5ml 2xTY and added to a 4l ﬂask with
1l of culture medium (2xTY, 1% glucose, selection by
either kanamycin or chloramphenicol). Production
cultures were grown shaking at either 37 Co r2 0  C
(depending on the previous screening result) to an OD
of around 0.5 and then induced with 0.5mM IPTG.
Expression was stopped after 3h (37 C) or after 17h
(20 C) and cells were harvested by centrifugation for
15min at 6000g and 4 C, washed once in 15ml PBS,
weighed and stored at  80 C (20 C cultures were
processed immediately). Pellets were resuspended in 5ml
binding buﬀer [25mM Tris–Hcl, 20mM imidazole, 0.5M
NaCl, 10% glycerol, pH 7.4, supplemented with
‘Complete’ protease inhibitor (Roche)] at 1 tablet per
50ml for each gram of pellet and passed twice through a
French press at about 10000psi pressure. The lysate was
clariﬁed by 30min centrifugation at 50000g and 4 C
and then mixed with 5ml Ni-NTA Agarose resin
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a rotator for 30min at 4 C. The resin was washed (1min
centrifugation at 2000g) ﬁrst with 30ml binding buﬀer,
then twice with 30ml washing buﬀer (25mM Tris–Hcl,
40mM imidazole, 0.5M NaCl, 10% glycerol, pH 7.4)
and protein was eluted by gravity ﬂow with 10ml
elution buﬀer (as above but with 0.5M imidazole) or by
centrifugation (2min at 2000g) with 2 5ml of the same
buﬀer. Eluates were ﬁltered over a Miracloth
(Calbiochem) to remove excess resin and passed into
centrifugal spin concentrators (GE Healthcare) with
10 kD size exclusion limit. Samples were then exchanged
into storage buﬀer (25mM Tris–HCl pH 7.4, 150mM
NaCl, 10% glycerol, 1mM DTT) by repeated
concentration and dilution, and aliquots of about 3mg/l
were stored at  80 C.
His-tag removal
A 1ml HISTrap HP column (GE Healthcare) was
equilibrated in storage buﬀer and loaded with 1.2ml
protein (2–5mg). The column was washed with 3–4
volumes buﬀer until the eluate remained colorless
(all treated samples contained ﬂuorescent protein). The
column was loaded with 1.2ml storage buﬀer containing
120U GST-tagged PreScission protease (GE Healthcare)
and incubated for 5h at 4 C. It was then eluted through a
1ml GSTrap HP column (GE Healthcare), equilibrated in
the same buﬀer. Fractions were pooled by color and then
concentrated and exchanged into HBS-P+ buﬀer
(Biacore) using a 5ml centrifugal spin concentrator with
10 kD exclusion limit (GE Healthcare).
SPR measurements
SPR experiments were performed on a Biacore T100
instrument (GE Healthcare) using HBS-P+ [10mM
HEPES, 0.15M NaCl, 0.05% (v/v) polysorbate 20,
50mM EDTA, pH 7.4] as running buﬀer. His-tagged
proteins (ligand) were immobilized to channel 2 and 4,
respectively, of a NTA sensor chip with 15s injection at
10ml/min. Dilution series of analyte protein were prepared
in running buﬀer and injected over all channels at
70ml/min ﬂow. Following each binding, the chip surface
was stripped with 60s injection at 10ml/min of
regeneration buﬀer (10mM HEPES, 0.35M EDTA, 8M
urea, 0.5M NaCl, pH 8.3) and re-loaded with 60s at
10ml/min of Nickel solution (500mM NiCl2 in running
buﬀer). The urea and salt supplements ensured the
removal of any unspeciﬁcally bound ligand which we
veriﬁed by reproducible base line and loading levels.
Regular control injections of buﬀer-only as well as ﬁxed
analyte concentrations showed constant loading and
binding curves over the course of each experimental
series. Binding traces were analyzed with the
manufacturer’s evaluation software version 2.0.1. and
ﬁtted to a kinetic two-state 1:1 binding model. For each
protein-loaded channel, we ﬁrst subtracted the signal of its
reference channel (i.e. 2–1or 4–3) and then the signal of a
buﬀer-only injection.
Leucine zipper interaction. His-tagged Zip2 mCitrine
(P22) was diluted to 600nM or 300nM and immobilized
to stable loading levels of about 1300RU or 640 RU
(response units). Dilution series of analyte protein
Zip1 mCherry (P21) without His-tag were prepared in
running buﬀer starting with protein concentrations of
2o r3mM. The analyte was injected for 60s at 70ml/min
and unbinding was monitored for 300s.
FKBP12–FRB interaction. Running buﬀers were
supplemented with 50nM rapamycin. Under these
conditions, we can assume a complete saturation of the
FKBP12 receptor protein with rapamycin [KD=0.2nM
(21)] that transforms the ternary protein–drug–protein
interaction into a bi-molecular protein–protein binding
(22). His-tagged FKBP12 mCherry (P04) or His-tagged
FKBP12 Citrine (P03) were diluted to 0.15mM with
running buﬀer containing 0.2mM rapamycin and
immobilized to loading levels around 110 or 170 RU
Following an additional 60s of equilibration at normal
ﬂow, P03 and P04 showed a constant signal decline of
about 0.5%/min and 2%/min, respectively. This decline
was near-linear, reproducible and was corrected for by
the subtraction of the buﬀer-only injection signal.
Dilution series of analyte protein FRB Cherry (P10)
without His-tag were prepared in running buﬀer with
50nM rapamycin and starting from protein
concentrations of 256nM. The analyte was injected for
300s at 70ml/min and unbinding was monitored for 400s.
FRET measurements
Measurements were performed on a plate reader (Tecan)
in black ﬂat-bottom 96-well plates. The donor protein was
diluted to 0.75mM in HBS-P+buﬀer (pH 7.4, see above).
The acceptor protein was diluted to 1.5mM in the same
buﬀer. Three samples were then prepared for each protein
pair: (i) 100ml donor+50ml buﬀer, (ii) 100ml buﬀer+
50ml acceptor, (iii) 100ml donor+50ml acceptor. Donor
and acceptor were thus used at an equimolar
concentration of 0.5mM in 150ml volumes. Each sample
was prepared in six replicas on a single plate and was
subjected to two diﬀerent measurement regimes for the
detection of either donor quenching or sensitized
acceptor emission. Excitation and emission wavelengths
for the four scenarios are listed in Table 1. The
platereader’s bandwidth required a gap of, at least,
30nm between excitation and emission wavelength and
excitation was therefore sometimes shifted away from
the donor’s absorption peak. In case of FKBP+FRB
input interactions, measurements were performed before
and after adding 2ml7 5 mM rapamycin to a ﬁnal
concentration of 1mM. Extinction coeﬃcients at
diﬀerent wavelenghts were determined on a Nanodrop
spectrophotometer (Thermo Scientiﬁc) using two diﬀerent
constructs each for mCerulean (P05, P12), mCitrine
(P19, P22), and mCherry (P04, P21).
Data analysis. FRET eﬃciencies were determined with
two complementary intensity measurements. (i) The
decrease in donor emission (donor quenching) was
quantiﬁed by comparing donor ﬂuorescence intensities
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The donor-based FRET eﬃciency ED is then calculated
as:
ED ¼ 1  
F D
AD
F D
D
ð1Þ
where F D
D is the ﬂuorescence intensity of the donor-only
sample measured at the donor emission peak  D
em. F D
AD
is the ﬂuorescence of the combined donor + acceptor
sample. Its raw value needs to be corrected for the
acceptor-only ﬂuorescence at the same wavelength:
F D
AD ¼ F D
AD0   F D
A . Although in practice, this acceptor
‘bleed-through’ remained always negligible.
Alternatively, (ii) the increase in sensitized acceptor
emission was quantiﬁed by comparing acceptor
ﬂuorescence intensities with and without donor protein.
Again, all samples were excited at, or close to the
donor’s maximum absorption but, this time, ﬂuorescence
intensities were recorded at the acceptor emission peak
 A
em. The acceptor-based FRET eﬃciency EA is then
calculated as:
EA ¼
  D
A
  D
D
F A
AD
F A
A
  1

ð2Þ
" D
D and " D
A denote the donor and acceptor extinction
coeﬃcient at the same donor excitation wavelength (see
below). F A
A is the acceptor-only ﬂuorescence measured at
the acceptor emission maximum  A
em (after excitation
at the donor absorbance peak). F A
ADis the acceptor
ﬂuorescence of the combined donor+acceptor sample.
It needs to be corrected for the donor-only contribution
to the signal: F A
AD ¼ F A
AD0   F A
D . Unlike in the donor
quenching regime, both FRET pairs show a sizable
emission overlap between donor and acceptor, and this
correction is therefore important. Extinction coeﬃcients
are usually only published for a ﬂuorophore’s absorbance
maximum (" max). Oﬀ-peak coeﬃcients like " D
A were
determined from the absorbance Að Þ normalized to the
absorbance maximum AðmaxÞ:
 ð Þ¼
Að Þ  max
AðmaxÞ
ð3Þ
and are given in Table 2.
The measurements of donor-only, acceptor-only and
donor+acceptor samples were individually averaged
over six replicas each and the error of the ﬁnal FRET
eﬃciency was derived from standard error propagation
of independent variables. We moreover performed an
alternative analysis based on the fact that the
FKBP:FRB interaction can be chemically ‘switched on’.
Rather than using donor- or acceptor-only samples as
reference for the FRET-oﬀ state, we directly compared
donor or acceptor ﬂuorescence before and after saturating
the system with rapamycin. Donor-based FRET eﬃciency
was then determined from a single sample, with the un-
induced ﬂuorescence replacing F D
D in Equation 1.
Likewise, we replaced F A
A in the acceptor emission
protocol (Equation 2). Nevertheless, while the donor
quenching can now be measured on a single sample, the
calculation of the acceptor-based FRET eﬃciency still
requires a separate donor reference to correct for the
donor signal ‘bleeding’ into the acceptor emission
window.
RESULTS
The BioBrick cloning format
The BioBrick standard (18,19) allows biological engineers
to easily assemble any combination of parts by the
iterative application of a single low-cost protocol.
BioBrick-formatted DNA is wrapped by a standard
preﬁx and a standard suﬃx sequence each containing a
set of two restriction sites. The two inner restriction sites
generate compatible cohesive ends which, after ligation,
produce a mixed site that is not recognized by either
restriction enzyme (18). This allows the iterative fusion
of two BioBricks into a single new BioBrick, which can
then be fused in a new round. The original BioBrick
assembly format is documented as BioBrick Foundation
Request For Comments number 10 or, in short, BBF
RFC 10 (18). It is widely used, in particular, by student
teams participating in the annual international Genetically
Engineered Machine competition (iGEM) http://igem.org.
A large and growing number of BioBrick-formatted DNA
parts is available from the Registry of Standard Biological
Parts (‘the registry’, in the following) http://
partsregistry.org. Unfortunately, the original BBF RFC 10
standard was not designed for the fabrication of
protein fusions. We thus adopted a modiﬁed format that
extends the original preﬁx and suﬃx sequences by a new
set of compatible inner restriction sites (AgeI and
NgoMIV). The format is documented as BBF RFC 25
(20) and remains backward-compatible with the older
standard. Finished fusion proteins can therefore be
combined with the existing collection of parts using
RFC 10 assembly.
Table 2. Extinction coeﬃcients in M
 1cm
 1
 maxa   max  435  495  516
mCerulean 433nm 43000
b
mCitrine 516nm 77000
b 2400 33000
mCherry 587nm 72000
b 9100 16200
Exerimental extinction coeﬃcients for diﬀerent wavelenghts.
aAbsorbance maximum.
bTaken from ref. (23). The remaining values were measured here.
Table 1. FRET measurement parameters
FRET pair Donor quenching Acceptor emmission
 ex  em  ex  em
mCerulean ! mCitrine 435 480 435 530
mCitrine ! mCherry 495 530 516 610
Excitation and emission wavelengths (in nm) used for diﬀerent FRET
pairs.
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ligation of two parts A and B into a third vector
backbone. A rotation between three diﬀerent antibiotic
resistancies allows to select for the target vector without
the need to gel-purify A or B plasmid restrictions
(3A assembly). The construction vectors pSB1AC3,
pSB1AK3 and pSB1AT3 with three diﬀerent antibiotic
resistancies can be, in theory, used for both BBF RFC 10
and RFC 25 assembly reactions. However, three NgoMIV
restriction sites in the tetracycline resistance cassette of
pSB1AT3 render this plasmid incompatible with the
BBF RFC 25 protocol. For consistency, we adapted all
three vectors to BBF RFC 25. The modiﬁed construction
vectors are denoted pSB1AC3F, pSB1AK3F and
pSB1AT3F (F for fusion) and are available from the
Registry under part numbers J18901, J18902 and J18903.
A collection of basic protein parts
Our initial collection of basic protein building blocks is
listed in Table 3. All protein parts were codon optimized
for expression in E. coli, adapted to the BBF RFC 25 (20)
BioBrick format (18,19) and gene-synthesized from
scratch.
Our parts list includes the most popular tags for protein
detection and aﬃnity puriﬁcation—Hexahistidine (24),
StrepII (25), FLAG (26), and GST (27). These are
complemented by recognition sites for TEV (28) and
preScission (29) proteases as well as ﬂexible Glycine-
Serine linkers of diﬀerent lengths. Our DNA assembly
method allows to place these peptides in frame, in any
order and at either ends or within a synthetic fusion
protein. Taken together, our list therefore covers the
fusion constructs that are most commonly used in
modern protein puriﬁcation protocols.
Another set of parts allows the triggering (input) of
protein–protein interactions. ZipE34 and ZipR34 encode
for a pair of leucine zippers that were rationally designed
for constitutive, high-aﬃnity heterodimeric binding (30).
Alternatively, the drug-induced interaction between
FKBP12 and FRB (31,22) is a widely used system that
puts the co-recruitment of any two proteins under the
control of rapamycin. Both interaction devices are
characterized in dedicated sections below. A third
interaction pair remains less established and here we
only report the expression and puriﬁcation of the LOV2
domain from Arabidopsis phototropin 1. According to one
report (32), this domain should undergo a light-induced
homodimerization.
We set out to detect protein–protein interactions by two
diﬀerent mechanisms: either through the complementation
of enzyme fragments (33,34) (protein complementation
assay, PCA) or through FRET between ﬂuorescent
proteins (35). Parts I757011 and I757012 encode for two
fragments of an interaction reporter that would
reconstitute TEM-1 b-lactamase activity (36). The two
parts were designed by the Freiburg iGEM 2007 team
based on an engineered variant of this enzyme (37).
Another set of popular complementation systems
converts protein–protein interactions into light signals.
A recent implementation of this assay is based on the
re-assembly of split luciferase from Gaussia princeps (38)
and promised improved signal intensity and reversibility.
Unfortunately, as we describe in further detail below,
Table 3. Protein parts provided in this study
ID
a Nickname Description Size
b Source
c Related
d References
J18912 T7start T7 promoter, RBS, start codon for expression in E. coli 83 pET3a
J18913 T7stop T7 terminator 135 pET3a
J18914 FLAG FLAG epitope tag (DYKDDDDK) 24 (26)
J18915 3xFLAG 3-repeat FLAG epitope tag 72 (26)
J18909 His6 Hexahistidine aﬃnity tag 18 K157011 (24)
J18916 StrepII StrepII aﬃnity tag 24 pET52b K157012 (25)
J18917 GST Glutathione S-transferase tag 687 pGEX-2T (27)
J18918 TEVsite TEV protease cleavage site 21 K128002 (28)
J18919 preSCsite PreScission protease cleavage site 24 (29)
J18920 1xGS 2 aa ﬂexible Glycine–Serine linker 6 (42)
J18921 3xGS 6 aa ﬂexible Glycine–Serine linker 12 (42)
J18922 5xGS 10 aa ﬂexible Glycine–Serine linker 30 (42)
J18923 ZipE34 Engineered leucine zipper 129 (30,43)
J18924 ZipR34 Engineered leucine zipper 129 (30,43)
J18925 FKBP12 FKBP12 (FK506-binding protein) 321 (44,31)
J18926 FRB Engineered FKBP12-rapamycin-binding domain FRB(T2098L) 279 (44,45)
J18927 LOV2 Arabidopsis phototropin 1 LOV2 domain 414 (32)
I757011 bla-frag1 TEM-1 b-lactamase fragment 1 525 iGEM 2007 (36,37)
I757012 bla-frag1 TEM-1 b-lactamase fragment 2 270 iGEM 2007 (36,37)
J18928 gLuc-frag1 Gaussia luciferase fragment 1 276 (38)
J18929 gLuc-frag2 Gaussia luciferase fragment 2 228 (38)
J18930 mCerulean Engineered cyan ﬂuorescent protein 714 (39)
J18931 mCitrine Engineered yellow ﬂuorescent protein 714 (40)
J18932 mCherry Engineered red ﬂuorescent protein 705 (41)
aID in registry of standard biological parts.
bLength in base pairs.
cSource of amino acid sequence, if not literature.
dClosely related parts.
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luciferase fragments failed due to issues pertaining to
folding and toxicity. We therefore focused our eﬀorts on
the FRET-based interaction readout and provide three
engineered, monomeric variants of ﬂuorescent proteins:
mCerulean (cyan) (39), mCitrine (yellow) (40) and
mCherry (red) (41). The three proteins can be combined
into two diﬀerent FRET pairs, where mCitrine either
accepts FRET from mCerulean or acts as FRET donor
for mCherry. Both scenarios are characterized below.
The parts list is completed by two cassettes for the
initiation as well as termination of transcription and
translation under the control of T7 polymerase. The
start cassette includes a strong T7 promoter, E. coli RBS
and start codon. The stop cassette begins with two
consecutive stop codons (tagtga) followed by the T7
terminator. Both sequences were adapted from the
prototypical expression vector pET3a (Novagen): we
deleted an XbaI site, added stop codons and introduced
the extended BioBrick preﬁx and suﬃx according to BBF
RFC 25 (20). Initially, the RFC 25 BioBrick extension was
only intended for protein-coding sequences. However, as a
matter of convenience, the new parts J18912 and J18913
allow us to complete a full expression construct with the
same protocol that is also used for the assembly of the
protein coding region itself. The ﬁnished expression
construct is self-contained. There is no need for further
sub-cloning and expression is initiated directly from the
assembled part in the standard BioBrick construction
vector.
Complete sequence and additional information for all
parts is available from the Registry under the IDs given in
Table 3.
Construction of synthetic proteins from standard parts
We optimized the BioBrick assembly protocol for the
parallel construction of composite fusion proteins from
individual parts. Our modiﬁed work ﬂow is outlined in
Figure 1. Compared to the original protocol, we simpliﬁed
liquid handling, reduced reagent volumes and adapted
most of the process for the parallel processing of many
assemblies on a 96-well plate format. Using this protocol,
we have assembled expression constructs for 25 synthetic
two-domain fusion proteins. The overall architecture
of our constructs is described in Figure 2. Table 4
summarizes the detailed composition of all synthetic
proteins. All constructs comprise seven BioBrick
components and share the same architecture, with a
10 amino acid ﬂexible linker separating two globular
interaction input and readout domains that are followed
by a preScission cleavage site and hexahistidine tag for
aﬃnity puriﬁcation. Complete nucleotide sequences are
given in the Supplementary Data and are available
online from the Registry.
As shown schematically in Figure 2, six cloning
reactions were needed for the assembly of a single fusion
construct. Yet, several intermediate assemblies of two or
three basic parts could be re-used for the construction of
diﬀerent targets and, under ideal conditions, the overall
list should have required only about 70 steps. Not only
Figure 2. Assembly of synthetic protein constructs from standard parts. Expression constructs for fusion proteins were built in several iterative steps
using the pairwise BioBrick assembly protocol. Parts could be assembled into any order but here we adhered to a single domain architecture. Only
positions of input and readout domain were occasionally swapped. All part boundaries are separated by the assembly ‘scar’ sequence Thr–Gly.
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but also owing to the repetition of failed steps we,
nevertheless, performed more than 150 cloning reactions
in total. Single reactions typically yielded between 50%
and 100% positive clones. By way of example, the
success rate of each construct’s ﬁnal assembly round is
given in Supplementary Table S1. Negative control
reactions, lacking either part A or B, gave between zero
and four colonies. The ligation-based process was not
prone to point mutations and there was no need to
sequence every intermediate product.
Occasional cloning failures often followed systematic
patterns and we thus also document yields of less eﬃcient
assembly scenarios in Supplementary Tables S2 and S3. In
particular, success rates were lower for the fusion of very
short fragments or when parts were deployed directly from
the gene synthesis vector pMA rather than from the
standard pSB1 vector backbone. Counts of false positive
transformants were moderately increased in the ‘mixed
backbone scenario’ (pMA+pSB1, Supplementary Table
S2), increased further if one of the parts was short and
became, for unknown reasons, often unmanageable if
both parts were excised from pMA (Supplementary
Table S3). The assembly of some additional target
constructs (combinations of luciferase or lactamase
fragments 2 with leucine zipper domains) was given up
after repeated failures to complete the fusion with
T7start and T7stop. Other, more sporadic, assembly
failures appeared unrelated to backbone or input parts
and could manifest themselves in both lack of
transformants or excessive false positive rates. Some
were resolved by a simple repetition. Others indicated
issues of quality control—sequencing of every single
cloning intermediate would have been prohibitively
expensive and errors could therefore occasionally
propagate through diﬀerent rounds of assemblies. Such
eﬀects were limited by redundancy: we archived two
independent clones of each assembly step but could also
bypass some bottlenecks on alternative assembly paths.
All ﬁnal constructs and only selected intermediate steps
were veriﬁed by sequencing.
Protein expression eﬃciency
Our small-scale puriﬁcation screen of all 25 synthetic
protein constructs revealed widely varying expression
levels. Detailed results are given in Table 5 and
summarized in Figure 3A. Indeed, a similar variation
could also be expected for the heterologous production
of natural proteins. Two clones of each construct were
tested at two diﬀerent expression temperatures (37 C
and 20 C). Here, we only report values for the best
performing temperature and clone. In fact, protein yields
can diﬀer even between two clones grown under equal
conditions and harboring the same construct.
Overexpression of the heterologous protein puts a heavy
burden on the cell. This leads to a high selective pressure
and some host cell populations adapt better or worse or,
occasionally, also escape protein production. For some of
the more striking examples, Figure 3A includes cell
densities and protein yields from the second clone grown
under the same conditions: two clones of P19, grown in
parallel at 37 C, gave similar protein yields. Yet, in one
case, the protein remained fully soluble, whereas in the
other case, virtually all of it was deposited in inclusion
bodies. A similar pattern was observed for the expression
of P15 in E. coli strain BL21-DE3-pLysE (see below) and
the production of P19 diﬀered by one order of magnitude
between seemingly identical clones of the same strain.
There were 12 constructs for which the standard screen
did not turn up any detectable protein in any clone at
either temperature. The majority of the latter also
showed sharply decreased growth rates (e.g. P13–P17)
indicating that these synthetic proteins were toxic for
their expression host. The 12th failure, P18, showed
signs of plasmid loss and we could retrieve a well-
expressing clone in a later test (not shown). Toxicity
issues were not occurring at random—essentially,
expression failed for all but one design containing either
the split b-lactamase or luciferase fragments. Expression
worked, to varying degrees, for every other protein.
We tried to rescue the production of nine split luciferase
reporters and subjected them to a second screen optimized
for the expression of toxic proteins. Conditions were
modiﬁed to reduce the leaky expression of the lac-
repressed T7 polymerase before the actual induction of
protein production with IPTG. We switched growth
from rich to normal LB medium in order to reduce
premature lac activation due to yeast galactosides (46).
Moreover, we transferred these constructs into a
Table 4. Synthetic proteins constructed in this study
ID Composition
a Size Registry
Domain1  ½ GS 5   domain2 ./H6 (kD) ID
b
P01 FKBP Luciferase 1 25.2 J18933
P02 FKBP Luciferase 2 23.5 J18934
P03 FKBP mCitrine 42.1 J18935
P04 FKBP mCherry 41.9 J18936
P05 FKBP mCerulean 42.1 J18937
P06 FKBP b-lactamase 1 34.6 J18938
P07 FKBP b-lactamase 2 24.9 J18939
P08 FRB Luciferase 1 24.6 J18940
P09 FRB Luciferase 2 22.9 J18941
P10 FRB mCherry 41.2 J18942
P11 ZipE34 Luciferase 1 18.4 J18943
P12 ZipE34 mCerulean 35.2 J18944
P13 ZipR34 Luciferase 2 16.7 J18945
P14 ZipE34 b-lactamase 1 27.8 J18946
P15 LOV2 Luciferase 1 29.5 J18947
P16 LOV2 Luciferase 2 27.8 J18948
P17 Luciferase 1 LOV2 29.5 J18949
P18 mCitrine LOV2 46.5 J18950
P19 FRB mCitrine 40.7 J18951
P20 FRB mCerulean 40.6 J18952
P21 ZipE34 mCherry 35.0 J18953
P22 ZipR34 mCitrine 35.5 J18954
P23 LOV2 mCitrine 46.5 J18955
P24 LOV2 mCerulean 46.3 J18956
P25 mCerulean LOV2 46.3 J18957
aComposition of fusion proteins—all proteins follow the same layout of
domain 1, GS linker, domain 2, pre-Scission restriction site (./) and
polyhistidine tag (H6); see text for details.
bID in Registry of Standard Biological Parts (http://partsregistry.org);
due to part assembly, all proteins start with the sequence MTG and end
with TG. Proteins labeled in bold face were puriﬁed on large scale.
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of T7 polymerase is counteracted by T7 lysozyme (47). As
another ‘stress avoiding’ measure (46), the new screen was
performed at 20 C temperature both before and after
induction. P04 and P12 were included as controls. The
modiﬁed conditions led to moderate production of
several additional proteins (Figure 3). However, they did
not provide us with a matching pair for the in vitro
characterization of the luciferase interaction readout
device. Overall, our standard expression screen generated
synthetic protein for 14 out of our 25 constructs, and the
modiﬁed screen turned up some, albeit typically low,
quantities for an additional three from the putatively
toxic list. The three rescued proteins (P11, P15 and P17)
represent diﬀerent combinations of luciferase fragment 1
with either the LOV2 or ZipE34 domain.
Yields of the successfully overexpressed proteins still
display considerable variation–from close to zero to over
1000ng/ml in the elution volume. Indeed, a large part of
this variation can be explained in terms of mRNA
secondary structure formation limiting the rate of
translation initiation (48–50). Figure 3B correlates
protein yields from the two expression screens (normalized
to cell count) with a recently developed score for
translation initiation eﬃciency (51). The score of RBS
calculator is based on only the sequence surrounding the
start codon and the values for each leading domain are
given in Table 6. The calculation incorporates several
binding terms for the interaction between ribosomal and
messenger RNA. In our case, the aﬀected sequences are all
constant and our constructs merely diﬀer in the coding
region following the ﬁrst three codons. The formation of
intra-mRNA secondary structure remains therefore the
only term of relevance. Taken together, issues of toxicity
and mRNA secondary structure appeared to be the two
major factors controlling protein production.
Interaction input device—leucine zipper
Leucine zipper pairs oﬀer arguably the most simple and
best understood protein–protein interaction partners
available so far (52). Here, we have chosen two short (43
aa) but tightly interacting helices that form a parallel
heterodimeric bundle. ZipE34 and ZipR34 are the pair
with highest aﬃnity and selectivity among a larger set of
rationally designed variants (30). They are derived from
the B-Zip domain of the chicken transcription factor VBP
and were published along with several mutants of varying
aﬃnities as constructs B-EE34 (I) and A-RR34. The same
pair, as well as two of the lower aﬃnity variants, have
already been utilized for the synthetic recruitment of
Table 5. Protein expression yields
ID Protein BL21-DE3 37 C
a BL21-DE3 20 C
b DE3-pLysE 20 C
c
OD Soluble
(ng/ml)
Insol. OD Soluble
(ng/ml)
Insol. OD Soluble
(ng/ml)
Insol.
P01 FKBP gLuc-frag 1 2.8 0 0 2.7 0 0
P02 FKBP gLuc-frag 2 0.8 0 0 2.5 0 0
P03 FKBP mCitrine 3.6 50 275 8.3 184 0
P04 FKBP mCherry 3.1 367 n.d. 8.4 597 n.d. 3.4 367 140
P05 FKBP mCerulean 3.7 472 0 8.0 137 0
P06 FKBP bla-frag 1 1.5 0 0
P07 FKBP bla-frag 2 0.9 0 0
P08 FRB gLuc-frag 1 1.1 0 0 0.3 0 0
P09 FRB gLuc-frag 2 2.0 315 0 0.6 25 0
P10 FRB mCherry 1.6 283 0 2.0 93 n.d.
P11 ZipE34 gLuc-frag 1 0.8 0 0 0.8 43 0
P12 ZipE34 mCerulean 0.8 0 0 1.2 129 0 2.6 34 0
P13 ZipR34 gLuc-frag 2 0.2 0 0 2.0 0 0
P14 ZipE34 bla-frag 1 0.2 0 0 0.3 0 0
P15 LOV2 gLuc-frag 1 0.4 0 0 0.3 0 0 3.6 0 77
P16 LOV2 gLuc-frag 2 0.3 0 0 0.6 0 0
P17 gLuc-frag 1 LOV2 0.2 0 0 0.5 0 0 2.3 0 1084
P18 mCitrine LOV2 3.7 30 0 6.0 247 0 2.5 179 274
P19 FRB mCitrine 4.2 0 650 8.2 0 0
P20 FRB mCerulean 5.8 488 0
P21 ZipE34 mCherry 2.7 384 0 3.7 278 n.d.
P22 ZipR34 mCitrine 2.7 20 0 3.8 226 0
P23 LOV2 mCitrine 3.2 0 n.d. 4.8 305 10
P24 LOV2 mCerulean 1.2 0 0 3.8 226 0
P25 mCerulean LOV2 2.8 21 38 8.2 301 19
Protein yield from expression screens under diﬀerent conditions. Protein constructs and IDs are the same as in Table 4. Cells were grown in 4ml,
proteins were puriﬁed on Ni2þ aﬃnity resin, probed by western blot and positive fractions quantiﬁed by capilary electrophoresis. Two clones each
were screened under each condition and here we only report the result of the clone with the highest protein yield/cell. See text for details.
aStandard screen in strain BL21-DE3 at 37 C.
bStandard screen in strain BL21-DE3 at 20 C.
cToxic screen in strain BL21-DE3-pLysE at 20 C. OD, cell density (OD600); soluble protein concentration in soluble fraction; insol protein
concentration in insoluble fraction; n.d., a weak band was observed in the insoluble fraction but was not quantiﬁed.
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signaling scaﬀold (43). Based on thermal denaturation
experiments, the peptides were reported to interact with
a dissociation constant of 6.1nM.
We sought to characterize this interaction more directly
and subjected two of our ZipR34 and ZipE34 containing
proteins to SPR experiments. The His tag of protein P21
(ZipE34 mCherry) was removed by proteolysis with
preScission protease. Unmodiﬁed P22 (ZipR34 mCitrine)
was then in turn immobilized via its remaining His tag on
the NTA sensor surface and exposed to varying
concentrations of its binding partner P21. Binding and
unbinding traces of one experiment are shown in
Figure 4. Data were ﬁt to a kinetic 1:1 binding model
implying a simple two state reaction. Averaging over
three experiments, we determined an association rate
A
B
Figure 3. Protein expression screens. (A) Absolute protein concentrations and cell densities (green) after expression and puriﬁcation under standard
conditions (left) or under conditions optimized for toxic proteins (right). Concentrations in soluble and insoluble fractions are stacked on top of each
other. Detailed data are listed in Table 5 and here we only show the clone and condition with highest yield/OD. (B) Control of protein expression by
RBS obstruction. Total protein yields from (A) were normalized to cell density (OD) and are mapped against the RBS calculator score (51) reporting
on the formation of mRNA secondary structure. Proteins with no or very low expression are denoted by open symbols and were not considered for
the linear regression. The protein ID corresponding to each data point is shown in Supplementary Figure S1. The RBS score (here divided by 1000)
considers only a sequence window surrounding the translation initiation site and is thus identical for constructs that share the same leading domain.
Some constructs with zero expression therefore collapsed into the same data point.
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koff ¼ 1:7   10 3   1:1   10 4s 1 corresponding to an
observed equilibrium dissociation constant
KD ¼ 83:0   8:9nM. The two-state model ﬁtted the data
well (average  2 ¼ 0:62   0:27), except at the highest
analyte concentrations above 2mM, where we observed
systematic deviations (data not shown). These were
excluded from the analysis, and as such we note that the
simple two-state assumption may not be accurate for high
local concentrations of the two binding partners. We did
not detect any homodimeric binding between either
ZipE34 or ZipR34 even at the highest analyte
concentrations of 3mM (data not shown).
Interaction input device—FKBP12:FRB (T2098L)
The rapamycin-induced interaction between FKBP12
(FK506 binding protein) and FRB (FKBP–Rapamycin
binding domain) can be considered a textbook example
of a re-usable interaction device (31) [see also references
in our review (4)]. However, rapamycin is a potent
immunosuppressor with antibiotic properties and can be,
depending on cellular context, toxic or cytostatic (53). We
replaced the wild type FRB from human mTOR by a FRB
variant with mutation T2098L (54). This single mutation
allows to trigger the FKBP12:FRB interaction with a non-
toxic rapamycin derivative, AP21967, and is supposed to
have little eﬀect on rapamycin binding (54). At
convenience, the interaction can thus be stimulated with
either compound. Kinetics and equilibrium constants of
the wt ternary FKBP:rapamycin:FRB interaction have
already been characterized (22). However, quantitative
data for the FKBP:rapamycin:FRB(T2098L) system
have so far not been available.
As before, we used the His-tag of one binding partner,
now P04 FKBP mCherry, for immobilization onto the
NTA sensor surface, proteolyically removed the His-tag
from the binding partner, P10 FRB mCherry, and
analyzed their interaction by SPR. Following the same
strategy as Banaszynski and colleagues (22), we saturated
the system ﬂow with 50nM rapamycin. At this
concentration, we can assume the complete saturation of
the immobilized FKBP with rapamycin [KD=0.2nM
(21,22)], while the interaction between FRB and
rapamycin remains negligible [wt KD=26mM (22)].
Experimental traces of binding and unbinding are
shown in Figure 4A. The kinetic ﬁt to a 1:1 binding
model gives a dissociation constant KD=0.24±0.03nM
(kon ¼ 8:0   105   0:36   105M 1s 1 and koff ¼
1:9   10 4   0:15   10 4s 1). These values are averaged
over four experiments at two diﬀerent chip loading levels.
Notably, steady state was not reached even at very high
analyte concentrations, where the 1:1 binding model
became increasingly inadequate. Inline with expectations,
the FKBP:FRB(T2098L) interaction was strictly depending
on rapamycin. Even 1mM analyte concentrations gave no
detectable binding signal in the absence of the drug (data
not shown).
Interaction readout devices—FRET
Our list of protein parts (Table 3) contains three
ﬂuorescent proteins that can be combined into
two diﬀerent FRET pairs for real-time detection of
AB
Figure 4. Binding kinetics of interaction input devices. (A) Constitutive interaction between Leucine zippers E34 and R34 (proteins P21 and P22) at
analyte concentrations from 22 to 1500nM. (B) Rapamycin-induced interaction between FKBP12 and FRB(T2098L) (proteins P10 and P04) at
analyte concentrations from 0.25 to 32nM. SPR traces of binding and unbinding were ﬁtted to a 1:1 interaction model (red line).
Table 6. RBS calculator scores
Leading parts Score
T7start-FKBP 6691
T7start-FRB 9590
T7start-ZipE34 10031
T7start-ZipR34 3899
T7start-LOV2 2600
T7start-gLucFrag1 60698
T7start-mCitrine 17215
T7start-mCerulean 17215
The score predicts the eﬃciency of intiation of translation based on
mRNA secondary structure formation near the translation intiation
site. See ‘Materials and Methods’ section for details.
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had been speciﬁcally engineered for FRET applications
and acts as FRET donor for yellow ﬂuorescent protein
mCitrine (40). In the alternative setting, mCitrine is used
as FRET donor for the red acceptor protein mCherry (41).
In our engineering framework, each of the two pairs is
considered an ‘interaction readout device’. Each device
converts the input interaction between two attached
domains or peptides into a measurable FRET signal.
Our fusion constructs allowed us to characterize every
FRET pair in combination with diﬀerent input
interactions. All in all, we determined FRET eﬃciencies
for six diﬀerent pairs of synthetic proteins. These
experiments are easily performed on a standard plate
reader instrument and an in-depth description of
measurements and analysis can be found in the
‘Meterials and Methods’ section.
Overall, we determined four FRET eﬃciency values for
each protein pair involving FKBP and FRB—we followed
either donor or acceptor ﬂuorescence while using either
the external or internal (no rapamycin) reference. Only
two FRET eﬃciencies each (donor quenching or
acceptor emission) were determined for the connection
of leucine zipper input to mCerulean!mCitrine or
mCitrine!mCherry output. We have constructed fusion
proteins for all six combinations of, on the one hand,
FKBP or FRB binding domain and, on the other hand,
mCerulean, mCitrine or mCherry readout domain. This
allowed us to also perform ‘role swapping’ experiments,
where the FRET donor domain was either attached to the
FKBP or to the FRB part of the interaction input.
FRET eﬃciencies for the six diﬀerent pairs of
interacting proteins are shown in Table 7. The two
diﬀerent ways of determining the FRET-oﬀ state—either
with separate control samples or by measuring in absence
of rapamycin—were typically equivalent within or close to
error margins. More importantly, the role-swapped FRET
eﬃciencies were in good agreement for both the
mCerulean!mCitrine and the mCitrine!mCherry pair,
at least, when connected to the FKBP:FRB input. That
means, swapping donor and acceptor domain from one to
the other half of the interaction input pair did not aﬀect
the observed FRET eﬃciency. Note that this comparison
is more signiﬁcant as it has encompassed a much larger
range of possible experimental error. Ideally, for a given
system, both donor- and acceptor-based FRET
measurements should yield identical FRET eﬃciencies.
This is indeed what was seen for the two combinations
of FKBP:FRB input with mCerulean!mCitrine output.
However, the mCitrine!mCherry pair showed a marked
diﬀerence between acceptor- and donor-based
measurements. Gross experimental error could be ruled
out as both values were perfectly reproduced between
the domain-swapped experiments with diﬀerent protein
constructs. The discrepancy indicates a partial
inactivation of the donor (mCitrine) domain. The
misfolding or photoinactivation of some donor
ﬂuorophores would not aﬀect the donor-based
measurement of FRET eﬃciencies as every intact donor
would still be paired up with an intact acceptor and the
signal is normalized to the intact donor population.
However, defective donor domains would, indeed, dilute
the FRET signal measured on the acceptor side (55),
which is normalized to the intensity of (intact) acceptor
molecules. Conversely, a certain fraction of defective
acceptor would invert this eﬀect and lead to a relative
decrease of the donor quenching. The absence of such a
decrease from our mCerulean!mCitrine pairs would,
actually, suggest an approximately equivalent degree of
mCerulean inactivation. Both protein domains are
closely related (96% sequence identity) and similar
maturation eﬃciencies would therefore not be surprising.
Surprisingly, we observed only very low resonance
transfer when we connected our two readout devices to
the constitutive leucine zipper interaction. Furthermore,
the eﬃciencies from the diﬀerent setups do not give a
consistent picture, owing, probably, to the fact that
below eﬃciencies of 0.05, the underlying ﬂuorescent
changes were minor compared to the strong basal
emissions of donor and acceptor.
DISCUSSION
A protein interaction device framework
Natural signaling proteins are often composed of multiple
domains that integrate signals by cooperative binding and
Table 7. FRET eﬃciencies for diﬀerent combinations of interaction input and output devices
Protein pair FRET method
Donor quenching
a Acceptor emmission
b
Parallel
c ±rap.
d Parallel
c ±rap.
d
FKBP mCerulean ! FRB mCitrine 0.23±0.010 0.21±0.007 0.20±0.004 0.19±0.015
FRB mCerulean ! FKBP mCitrine 0.19±0.004 0.18±0.004 0.18±0.002 0.17±0.008
FKBP mCitrine ! FRB mCherry 0.28±0.006 0.25±0.003 0.10±0.010 0.10±0.012
FRB mCitrine ! FKBP mCherry 0.29±0.008 0.25±0.004 0.09±0.022 0.12±0.022
ZipE34 mCerulean ! ZipR34 mCitrine 0.001±3e-5 0.060±0.006
ZipR34 mCitrine ! ZipE34 mCherry 0.017±4e-4 0.021±0.015
aMeasuring quenching of donor ﬂuorescence.
bMeasuring sensitized acceptor emission.
cComparing independent samples with and without donor (external control).
dComparing ﬂuorescence before and after adding rapamycin (internal control).
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only the individual domains but also their interactions are
recurring in numerous variations of the same design
patterns across diﬀerent networks. This natural
modularity of interactions, rather than of mere proteins,
is the departure point for our concept of protein
interaction devices. We propose to ‘refacture’ protein–
protein or protein–peptide interactions into functional
devices for the construction of protein circuits. On a
functional level, devices would communicate by the
formation or release of protein interactions, leading to
co-recruitment or changes in the local concentrations of
attached domains. On a physical level, they would be
connected through protein fusions.
We explored strategies and methods that may become
critical for the routine design of protein systems.
Key issues are, in our opinion, the composition of
synthetic proteins from modular parts, the biophysical
characterization of protein devices, as well as their
physical connection and interplay.
From parts to DNA—design and assembly of
protein parts
As a proof of concept, we have assembled 25 synthetic
proteins, each from ﬁve protein parts and ﬂanked by
two non-coding parts for the regulation of expression
and translation. We set out from a small catalog of 24
basic building blocks. The design of this initial parts list
could tap into a large body of protein engineering
literature. In fact, variants of most parts had already
been used and re-used in various heterologous fusion
proteins. Classic cloning strategies are ill-suited for the
recombination of proteins from multiple unrelated
domains and linker segments. Moreover, also current
gene synthesis work ﬂows are not adapted to this task.
Our ﬁnal constructs are long but, actually, mere
recombinations of a small set of unique sequences.
Nevertheless, this redundancy would not translate to
cost savings as all would have to be synthesized de novo.
We thus adopted a hybrid approach combining the gene
synthesis of all basic parts with their assembly by a
standardized iterative cloning method (BioBrick
assembly) (18). The original BioBrick format does not
allow for protein fusions and we therefore applied a
modiﬁed, backwards-compatible method (BBF RFC 25)
optimized for the assembly of protein fusion constructs.
(20). Consequently, not only all our protein parts but also
ﬁnal constructs remain physically compatible with a large
collection of building blocks in the Registry of Standard
Biological Parts and could be integrated into larger genetic
circuits. On the downside, despite our further streamlined
protocol, cloning remained a time- and cost-consuming
bottleneck of the whole process. Faster, easily accessible
and more eﬃcient methods for the assembly of DNA from
recurring fragments are still wanting.
From DNA to proteins—production of synthetic proteins
A single established protocol for expression and
puriﬁcation was suﬃcient for the production of soluble
protein from many synthetic constructs (14 out of 25).
Three more could be recovered with a simple set of
routine modiﬁcations. It seems feasible to compile a
small set of consensus screens and protocols (56)
covering the puriﬁcation of most synthetic proteins. In
fact, thanks to the synthetic layout of our constructs we
could pinpoint two major factors explaining much of the
variation in expression. First, all the failing constructs
contained one of the artiﬁcially split protein domains.
Second, the expression levels of most remaining proteins
appeared to be controlled by RNA secondary structure
interactions between coding sequence and RBS.
Inadvertently, our data complement results of several
recent reports (49–51) on this correlation between the
obstruction of ribosomal binding and protein expression
levels. While our data set is much more sparse, it does add
quality to the relation. Previous work examined variants
of a single reporter protein in combination with diﬀerent
RBS sequences. Here, we show the inverse experiment.
While the RBS remained constant, very diﬀerent
domains were swapped into the N-terminal position and
tested in combination with several unrelated C-terminal
domains.
Notably, RBS obstruction has been known for some
time (48) and is accounted for by the codon optimization
algorithms of most gene synthesis providers. However,
our part sequences were, quite intentionally, optimized
outside their ﬁnal context and are supposed to be
re-usable in diﬀerent positions and with diﬀerent
expression systems. Here, we are reaching some
obvious limit of a purely parts-centric sequence design.
Similar side eﬀects may have to be accounted for at
various levels. Nevertheless, in this case, there is a
technical ﬁx (49): a short N-terminal part can be codon-
optimized for a given RBS and should uncouple the
remaining protein sequence from interference with
translation initiation.
RBS obstruction was unrelated to the outright
expression failure of several protein constructs. Issues of
mis-folding and aggregation are the most likely reasons
for the toxicity of split protein domains. A case in point
is luciferase fragment 1 (gLuc-frag1). Constructs
containing this domain did not express under
standard conditions but production of several proteins
containing this domain, for example P15 and P17,
could be rescued with the protocol optimized for toxic
proteins. Yet, as shown in Figure 3, the highest
growth rates were obtained for clones that channeled
the product into inclusion bodies where it could not
interfere with the cellular machinery. Furthermore,
Gaussia princeps luciferase contains ﬁve disulﬁde bonds
and even the intact enzyme is a diﬃcult expression
target (57). Complementation systems based on ﬁreﬂy
(58) or Renilla (59) luciferase may oﬀer a more robust
alternative. Experiences about expression levels and
solubility of proteins are of very practical importance
but remain often qualitative and hidden from
literature. The development of appropriate measurement
standards may be a worthy challenge for protein synthetic
biologists.
2658 Nucleic Acids Research, 2010,Vol.38, No. 8From proteins to systems—device characterization
Despite considerable eﬀorts (9,60,61), most standard
biological parts currently available are merely
standardized with respect to cloning and remain otherwise
uncharacterized. In particular, gene regulatory devices are
often sensitive to their cellular context and activities can
only be measured in relative terms. Measurement kits with
reference standards have been proposed as a solution (61).
In contrast, we can characterize proteins and their
interactions in vitro and assign absolute numbers to
many of their properties. Here, we have characterized
two protein–protein interactions, which we consider
prototypical ‘interaction input devices’, and combined
them with two diﬀerent FRET pairs that we consider
‘interaction readout devices’. Molecular interactions are
commonly characterized by their dissociation constant
KD. Yet, the kinetics of an interaction can often be
much more important and accurate modeling of system
dynamics requires on- and oﬀ-rates rather than
equilibrium binding constants (62,63).
We therefore subjected both a constitutive leucine
zipper and the drug-inducible interaction between
FKBP12 and modiﬁed FRB to SPR analysis. The
measurements conﬁrmed that both pairs functioned
correctly also in the context of fusion proteins. The
‘always on’ ZipE34:ZipR34 interaction was indeed
exclusively heterodimeric. The FKBP12:FRB binding
strictly depended on its inducer, rapamycin and switched
from practically zero background to a high-aﬃnity
interaction. As of yet, no kinetic parameters have been
determined for neither system, although a dissociation
constant was published for ZipE34:ZipR34 (30) and
SPR data were available for the interaction between
FKBP12 and wild type FRB (22).
The kinetically determined aﬃnity of the leucine zipper
(KD=83nM) was one order of magnitude lower than the
earlier value from thermal unfolding (KD=6.1nM).
However, discrepancies were to be expected. The tethering
to a much larger globular domain (mCherry) likely slows
diﬀusion of the free molecule. The fused domain may also
exert mechanical forces that counteract binding or
accelerate unbinding. In fact, this could serve as another
illustration of ‘side eﬀects’ between parts. Single-domain
controls and further experiments with other synthetic
fusion constructs would be needed to delineate and
properly account for these eﬀects.
In contrast, the aﬃnity for the rapamycin-induced
binding of FKBP12 to the modiﬁed FRB(T2098L)
appears higher than the aﬃnity published (22) for the
unmodiﬁed system (KD=0.24nM versus 12nM). A
moderate decrease in on-rate is more than compensated
by a two orders of magnitude lower oﬀ rate. The T2098L
mutation had been designed to accommodate the non-
toxic ‘rapalog’ AP21967 and was supposed to have no
or only minor inﬂuence on rapamycin binding. In fact,
more qualitative data, based on a reporter gene assay,
suggested a slightly detrimental eﬀect. On the other
hand, rapamycin is not a natural ligand of this system
and aﬃnity-increasing mutations seem therefore plausible.
Aside from the possibility of triggering synthetic
interaction systems, we also need means to follow their
dynamics. FRET assays can report molecular interactions
with high time and spatial resolution inside or outside of
cells without the requirement of co-factors. Unlike protein
complementation methods, modern FRET pairs do not
create interactions themselves and the signal is therefore
reversible. On the other hand, FRET lacks the signal
ampliﬁcation that is aﬀorded by enzymatic or genetic
interaction reporters. The signal is strongly distance
dependent and can be, for this reason, very sensitive to
the steric arrangement of the two FRET probes within a
complex. We have tested the interaction readout with two
FRET pairs by connecting them to the constitutive leucine
zipper and the inducible FKBP12:FRB interaction.
Despite rather long ﬂexible linkers between the
interaction input module and the readout pair,
FKBP12:FRB input was converted into good and
consistent FRET eﬃciencies. There was an excellent and
quantitative agreement between domain swapping
experiments, that means, donor or acceptor could be
equally connected to either of the interaction partners.
This perfect agreement of FRET eﬃciencies, in fact,
indicates the ‘correct functioning’ (42) of the long (14 aa
including assembly scars) and very ﬂexible linker that
uncoupled the dynamics of binding and reporter domain
and ensured the orientational averaging of acceptor and
donor ﬂuorophores (64). The comparison of acceptor- and
donor-based measurements across diﬀerent domain-
swapped pairs indicated a fraction of ‘dark’ or inactive
mCitrine domains which seems to equally apply to
mCerulean but not (or less) to mCherry. YFP, the
common ancestor of mCitrine and mCerulean is indeed
known for poor maturation rates (55) and, probably
also depending on expression conditions, some of this
problem appears to persist. Nevertheless, while there is
room for improvement, the input/output system presented
here may be quite suitable as a general purpose FRET
reference.
On the other hand, disappointing FRET signals from
the coupling to the leucine zipper remind of the challenges
in FRET probe design in particular and parts-based
protein composition in general. The interaction itself was
independently veriﬁed by SPR. Compared to the
FKBP12:FRB system, fusion to the leucine zipper
should lower rather than increase the distance between
FRET probes. The zipper’s lower aﬃnity, compared to
the FKBP:FRB device, should have had little
inﬂuence—measurements were taken at concentrations
well above the system’s KD (albeit not at full saturation
of the bound state). Also, the interaction dynamics
(koﬀ 10
 2s
 1) seem far too slow for aﬀecting nanosecond
time scale FRET processes. Issues may therefore have
arisen from a less favorable orientation of the
ﬂuorophores (64) or from end-fraying of the leucine
zipper (65), perhaps aggravated by the fusion with the
heavy GFP domains. Notably, this result would not
have been easily predicted from our deterministic
measurements on the system’s individual components.
Structure-based dynamic modeling may help to make
the connection of interaction input and output devices
Nucleic Acids Research,2010, Vol.38, No. 8 2659more predictable (66,67). Yet, for the time being,
experimental characterization remains a key requirement.
CONCLUSION
We here explored the feasibility of a parts- and device-
based approach to protein synthetic biology. Our model
work ﬂow started with the design of re-usable parts
capturing basic protein functionalities, followed by their
assembly into modular fusion proteins, the expression and
puriﬁcation of these proteins and, last not least, the
in vitro constitution and biophysical characterization of
simple interaction devices. Modular protein–protein
interactions hold promise as the functional building
blocks of larger systems. Their characterization and
refacturing into protein interaction devices could,
ultimately, become the basis of a versatile engineering
framework. We here provide tested building blocks and
protocols for the construction and rewiring of reference
interactions as well as their dynamic detection. Our proof
of concept experiments clearly demonstrate the feasibility
of parts-based protein design. They, nevertheless, also
revealed typical stumbling blocks: DNA assembly
remains a technical bottleneck, whereas protein expression
may be more amenable to rational optimization than
perhaps expected. Input and output interactions could
indeed be rewired in diﬀerent combinations. However,
their exact interplay was not always easily predicted
from the characterization of the individual components.
Rational engineering thus needs to be guided by
additional rules and reﬁned modeling tools. In fact,
simple interaction systems like the ones constructed here,
could provide a perfect test bed for exploring the
connection rules of both synthetic and natural signaling
modules. The comparison of synthetic constructs shed
light on FRET probe design and delineated factors
controlling protein expression. Thus, systematic domain
swapping among modular and idealized synthetic
proteins also proves a promising strategy for the study
of more basic questions.
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